Assessment superseded
RCT of metformin for sarcopenia prevention in older adults with prediabetes showed no reported effect size
This RCT examined whether metformin could prevent sarcopenia in older adults with prediabetes. The study was motivated by evidence that insulin resistance increases sarcopenia risk in older people. No effect size or outcomes data were reported in the abstract.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Feb 11, 2020 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- VA Office of Research and Development
- Published
- Feb 11, 2020
Sources
Primary source
- VA Office of Research and Development ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.